• Age ≥18 years.

• Histologically confirmed CD20+ mantle cell lymphoma.

• No prior anti-lymphoma treatment.

• Ann Arbor stage II-IV.

• ECOG performance status 0-2, no deterioration \>2 weeks before baseline or first dose.

• Younger subjects (\<65) must meet:

∙ Low to intermediate risk sMIPI (0-5)

‣ Ki67 \< 50%

‣ No TP53 mutation (NGS)

‣ Lesion diameter ≤5 cm

‣ Non-blastoid, polymorphic disease

• At least one assessable lesion per Lugano 2014 criteria.

• Adequate organ and bone marrow function during screening.

• Female subjects must use contraception as per local regulations.

⁃ Male subjects must agree to avoid sperm donation during the study and for 12 months post-rituximab.

⁃ Willing to undergo all required assessments and procedures, including swallowing capsules/tablets.

⁃ Able to understand the study's purpose and risks, and provide signed informed consent with authorization for the use of personal health information.